Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Muzamil Yaqub Want, Anna Konstorum, Ruea-Yea Huang, Vaibhav Jain, Satoko Matsueda, Takemasa Tsuji, Amit Lugade, Kunle Odunsi, Richard Koya & Sebastiano Battaglia. (2019) Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer. OncoImmunology 8:6.
Read now
Read now
Zigao Yuan, Jiwei Chen, Wenlu Li, Dan Li, Changjun Chen, Chunmei Gao & Yuyang Jiang. (2017) PARP inhibitors as antitumor agents: a patent update (2013-2015). Expert Opinion on Therapeutic Patents 27:3, pages 363-382.
Read now
Read now
Stefano Bogliolo, Chiara Cassani, Mattia Dominoni, Valentina Musacchi, Pier Luigi Venturini, Arsenio Spinillo, Simone Ferrero & Barbara Gardella. (2016) Veliparib for the treatment of ovarian cancer. Expert Opinion on Investigational Drugs 25:3, pages 367-374.
Read now
Read now
Articles from other publishers (12)
Yanhong Liu, Meiyan Wang, Wanru Liu, Jili Jing & Hongshuang Ma. (2022) Olaparib and Doxorubicin Co-Loaded Polypeptide Nanogel for Enhanced Breast Cancer Therapy. Frontiers in Bioengineering and Biotechnology 10.
Crossref
Crossref
Bingteng Xie & Aiqin Luo. (2022) Nucleic Acid Sensing Pathways in DNA Repair Targeted Cancer Therapy. Frontiers in Cell and Developmental Biology 10.
Crossref
Crossref
Jie Yan, Alexander Günter, Soumyaparna Das, Regine Mühlfriedel, Stylianos Michalakis, Kangwei Jiao, Mathias W. Seeliger & François Paquet-Durand. (2022) Inherited Retinal Degeneration: PARP-Dependent Activation of Calpain Requires CNG Channel Activity. Biomolecules 12:3, pages 455.
Crossref
Crossref
Jie Yan, Yiyi Chen, Yu Zhu & François Paquet-Durand. (2021) Programmed Non-Apoptotic Cell Death in Hereditary Retinal Degeneration: Crosstalk between cGMP-Dependent Pathways and PARthanatos?. International Journal of Molecular Sciences 22:19, pages 10567.
Crossref
Crossref
Tássia S. Tavares, Jakub Hofman, Alžběta Lekešová, Jana Želazková & Vladimír Wsól. (2020) Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3. Cancers 12:11, pages 3127.
Crossref
Crossref
Entaz Bahar, Ji-Ye Kim, Hyun-Soo Kim & Hyonok Yoon. (2020) Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist Expression. International Journal of Molecular Sciences 21:20, pages 7613.
Crossref
Crossref
Jaideep BanerjeeNiraj LodhiBao-Ngoc Nguyen. (2019) The Role of Poly(ADP-Ribose) Polymerase-1 in Cutaneous Wound Healing. Advances in Wound Care 8:12, pages 634-643.
Crossref
Crossref
Pamlea N. Brady, Anupam Goel & Margaret A. Johnson. (2019) Poly(ADP-Ribose) Polymerases in Host-Pathogen Interactions, Inflammation, and Immunity. Microbiology and Molecular Biology Reviews 83:1.
Crossref
Crossref
W Lee Kraus. (2019) PARP Inhibitors may be Beneficial in a Broader Range of Patients. Oncology & Hematology Review (US) 15:2, pages 66.
Crossref
Crossref
Ping Li, Wenlian Liu, Qian Xu & Changxiu Wang. (2017) Clinical significance and biological role of Wnt10a in ovarian cancer. Oncology Letters.
Crossref
Crossref
Dominic I. James, Kate M. Smith, Allan M. Jordan, Emma E. Fairweather, Louise A. Griffiths, Nicola S. Hamilton, James R. Hitchin, Colin P. Hutton, Stuart Jones, Paul Kelly, Alison E. McGonagle, Helen Small, Alexandra I. J. Stowell, Julie Tucker, Ian D. Waddell, Bohdan Waszkowycz & Donald J. Ogilvie. (2016) First-in-Class Chemical Probes against Poly(ADP-ribose) Glycohydrolase (PARG) Inhibit DNA Repair with Differential Pharmacology to Olaparib. ACS Chemical Biology 11:11, pages 3179-3190.
Crossref
Crossref
Lingxiao Wang, Feng Liu, Ning Jiang, Wenxia Zhou, Xinbo Zhou & Zhibing Zheng. (2016) Design, Synthesis, and Biological Evaluation of Novel PARP-1 Inhibitors Based on a 1H-Thieno[3,4-d] Imidazole-4-Carboxamide Scaffold. Molecules 21:6, pages 772.
Crossref
Crossref